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Abstract
Background—A high prevalence of reactivation of hepatitis B has been documented among 
immunosuppressed individuals in the inactive phase of chronic hepatitis B; However, the 
proportion of and the risk factors for reactivation are largely unknown among non-
immunosuppressed persons.
Objectives—Estimate the incidence rate of and risk factors for hepatitis B reactivation in a 
population-based cohort of persons in the inactive phase of chronic hepatitis B in Alaska.
Study design—A cohort of 414 Alaska Native Persons in the inactive phase of hepatitis B 
(HBV DNA < 2000 IU/mL and normal alanine aminotransferase (ALT) for 12 months) was 
followed-up for 10 years. Reactivation of hepatitis B was defined as HBV DNA ≥ 2000 IU/mL 
and ALT ≥ 40 IU/L. Cox-proportional hazards regression models were used to identify factors 
associated with reactivation.
Results—A total of 36 (9%) persons had reactivation during 2984 person-years of follow-up, 
with an annual incidence of 1.2%. Persons aged ≥50 years (1.8%) at study entry had the highest 
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incidence rates of reactivation although incidence rates were not significantly different by age 
group. Risk factors for hepatitis B reactivation were male sex (Hazard Ratio (HR) = 2.41; 95% 
Confidence Interval (CI): 1.17–4.96), HBV DNA ≥ 1000 IU/mL at study entry (HR = 7.61; 95% 
CI: 2.81–20.6), and HBV genotype B (HR = 6.08; 95% CI: 1.32–28.0).
Conclusions—The incidence of hepatitis B reactivation was low during the 10 years of follow-
up. However, given the higher risk of reactivation than their counterparts, males, and those with 
HBV DNA ≥ 1000 IU/mL need to be followed-up more frequently.
Keywords
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1. Background
Over 350 million persons worldwide and 730,000 persons in the United States have chronic 
hepatitis B virus (HBV) infection, a major cause of cirrhosis and liver cancer [1,2]. Almost 
20 years ago, the Alaska Native population has had one of the highest rates of chronic 
hepatitis B, and chronic liver disease was associated with higher proportion of deaths among 
American Indian/Alaska Native people compared to other racial/ethnic groups in the United 
States [3,4].
Three phases of chronic HBV infection are recognized: the immune tolerant phase, the 
immune active phase, and the inactive phase [5]. Although a high prevalence of reactivation 
of HBV infection has been documented among immunosuppressed individuals in the 
inactive hepatitis B phase [6], reactivation also might occur among non-immunosuppressed 
individuals. However, the proportion of persons in the inactive phase of chronic hepatitis B 
who will reactivate and the risk factors for reactivation are largely unknown [6]. Cohort 
studies assessing the incidence of and risk factors for hepatitis B reactivation among persons 
in the inactive phase of chronic hepatitis B are limited in number and the majority of studies 
recruited inactive carriers from hospitals [7,8], or blood banks [9,10]. Studies including 
population-based cohorts are lacking. Hence, it is unclear how frequently follow-up visits 
and testing should be performed among persons in the inactive hepatitis B phase. Current 
American Association for the Study of Liver Disease (AASLD) practice guidelines suggest 
that persons in the inactive phase should be followed every 6–12 months [11].
2. Objectives
We conducted this study to determine the incidence of and identify factors associated with 
hepatitis B reactivation in a population-based cohort of Alaska Native persons in the inactive 
phase of chronic hepatitis B.
3. Study design
3.1. Study population
Detailed information about the Alaska Native cohort has been described previously [12,13]. 
In summary, a mass population screening program for hepatitis B conducted during 1983–
1987 among 52,000 Alaska Native persons identified 1536 persons chronically infected with 
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hepatitis B. Of those, 1407 consented to participate in the cohort study and were contacted 
every 6 months for blood specimen collection. HBV DNA was tested at baseline and 
repeated whenever ALT levels were elevated and among persons with a family history of 
hepatocellular carcinoma (HCC) or who had one or more HBV DNA levels above 2000 
IU/mL.
For this study, we examined persons who fulfilled the National Institutes of Health (NIH) 
criteria for the inactive HBV phase between the dates of 10/01/2001 and 12/31/2010. As of 
10/1/2001, 1175 consented persons with chronic hepatitis B infection were still alive, and of 
those, a total of 414 met the study criteria for the inactive hepatitis B phase. The inactive 
HBV phase was defined as fulfilling the following three criteria on study entry: (1) most 
recent HBV DNA < 2000 IU/mL; (2) most recent hepatitis B e antigen (HBeAg) negative or 
antibody to hepatitis e antigen (anti-HBe) positive, and (3) alanine aminotransferase (ALT) 
<40 IU/L for at least 12 months. We excluded persons who were negative for HBsAg at 
study entry, and HBsAg-positive persons who were co-infected with hepatitis C or HIV. 
Reactivation of hepatitis B was defined as (1) HBV DNA ≥ 2000 IU/mL and (2) ALT ≥ 40 
IU/L. The occurrence of these events did not have to be simultaneous; the time of 
reactivation was considered the time of fulfillment of both events.
Basic demographic (age, sex, and ethnicity) and clinical information (age at first positive 
HBsAg, body mass index (BMI), ALT, HBV genotype, and HBV DNA levels) was 
abstracted to identify risk factors for hepatitis B reactivation. Body mass index was 
classified as normal (<25 kg/m2), overweight (25 ≤ BMI < 30 kg/m2), and obese (BMI ≥ 30 
kg/m2) [14].
The Institutional Review Boards of the Alaska Area and the Centers for Disease Control and 
Prevention approved the study protocol.
3.2. Laboratory testing
Enzyme-linked immunoassay (Abbott Laboratories, Irving, TX) was used to measure 
HBsAg, antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core 
(anti-HBc). The OneStep Hepatitis B ‘e’ Antigen Test Strip and the Maxi Test Anti-HBe 
Rapid Test were used to test for HBeAg, and anti-HBe, respectively, according to the 
manufacturer’s instructions (IND Diagnostic Inc., Delta, British Columbia, Canada). We 
validated both tests using sera previously tested with the Abbott Laboratories enzyme-linked 
immunoassay kits, which are no longer commercially available.
Real-time quantitative polymerase chain reaction (PCR), with a lower limit of detection of 
100 copies/mL (20 IU/mL) was used to determine HBV viral loads. Briefly, HBV DNA was 
extracted from stored serum specimens using the MagNA Pure Compact System and Total 
Nucleic Acid Extraction Kit I according to manufacturer’s instructions (Roche Applied 
Science, Indianapolis, IN). Subsequently, a 118-bp fragment of the core gene was amplified, 
and HBV viral loads were determined by comparison to a set of HBV DNA standards 
amplified in parallel with the samples being tested [15]. HBV genotyping was performed by 
polymerase chain reaction as previously described [16].
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Categorical data were reported as percentages while continuous variables were described 
using means and standard deviations. The annual incidence of hepatitis B reactivation was 
calculated using survival analysis by dividing the number of persons that had reactivation of 
their HBV infection by the total number of person-years of follow-up. We used Poisson 
regression to compare the incidence of reactivation across age groups, genotypes and 
categories of HBV DNA. Univariable Cox-proportional hazards regression was conducted to 
identify the variables associated with hepatitis B reactivation. Subsequently, we included 
those variables in the multivariable model to identify significant determinants of hepatitis B 
reactivation after controlling for all potential risk factors. Statistical analysis was conducted 
using STATA v. 10 and P-values <0.05 were considered statistically significant.
4. Results
The mean age of study participants at the time of entry into the study was 40.1 ± 14.3 years; 
43% were male. More than half were diagnosed with a positive HBsAg before the age of 20 
years. The ALT levels were within normal range for all cohort members, and 13% had HBV 
DNA ≥ 1000 IU/mL at study entry (Table 1).
This cohort was followed up for an average of 7.4 ± 1.9 years (median: 8.2 years; range: 
1.3–9.2 years), had a median of 10 (range: 1–83) ALT measurements (96.1% had three or 
more ALT and 84.1% had 5 or more ALT), and a median of 2 (range: 1–19) HBV DNA 
levels during the study period. A total of 36 (9%) inactive carriers developed reactivation of 
their HBV infection after an average of 5.8 ± 2.0 years (median: 6.7 years; range: 1.3–9.0 
years) of follow-up. The first elevated median HBV DNA level among those who 
reactivated was 3701 IU/mL (range: 2040–65,933 IU/mL) and 25% of those who reactivated 
had HBV DNA ≥ 10,000 IU/mL on their first elevated HBV DNA. Peak median HBV DNA 
levels among those who reactivated was 4379 IU/mL (range: 2040–973,173 IU/mL) and 
33% of those who reactivated had peak HBV DNA levels ≥10,000 IU/mL. Among the 36 
carriers who reactivated their hepatitis B infection, 11 had a maximum ALT > 100, and 31 
had at least one repeat HBV DNA level during the follow-up period. Of these, 19 (61%) had 
elevated HBV DNA on more than one occasion.
The annual incidence of reactivation of hepatitis B was 1.2% after 2984 person-years of 
follow-up (Table 2). The highest annual incidence rates of reactivation were found among 
inactive carriers who were ≥50 years old (1.8%) at study entry, however the incidence of 
reactivation was not statistically different across the various age groups (p = 0.06). The 
proportion of persons who had reactivation of infection increased with study time in both 
genders. However, a larger proportion of males had reactivation earlier during the study 
period (within 2–4 years) compared to females who generally experienced reactivation 6 
years after study entry (Fig. 1).
In the unadjusted analysis, persons aged 40–49 years at study entry had a lower risk for 
reactivation of infection than those aged 18–29 years (Table 3). Males were two times more 
at risk of reactivation than females. Ethnic group and age at first detection of a positive 
HBsAg were not significant determinants of reactivation. Almost one in four inactive 
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carriers of hepatitis B who had HBV DNA > 1000 IU/mL on study entry had reactivation, 
compared to only 4% of those with HBV DNA levels <29 IU/mL (Table 3). Furthermore, 
compared to inactive carriers having an HBV DNA < 1000 IU/mL at study entry, those with 
HBV DNA ≥ 1000 IU/mL had a significantly higher incidence of hepatitis B reactivation 
(32.5 per 1000 persons per year vs. 8.9 per 1000 persons per year, p < 0.01). Persons with 
HBV genotype B had a significantly higher cumulative incidence of reactivation (22%) 
compared to those with other HBV genotypes (9%).
Cox proportional hazards regression analysis showed that the risk of reactivation of hepatitis 
B was independently associated with age at study entry since persons aged 30–49 years at 
study entry had significantly lower risk for reactivation than those aged 18–29 years. In 
addition, male sex (Hazard Ratio (HR) = 2.41; 95% confidence interval (CI): 1.17–4.96), 
HBV DNA ≥ 1000 IU/mL at study entry (HR = 7.61; 95% CI: 2.81–20.6), and HBV 
genotype B (HR = 6.08; 95% CI: 1.32–28.0) were also significantly associated with 
reactivation of hepatitis B (Table 4). Of the 414 persons in the inactive phase of hepatitis B, 
19 (4.6%) were treated for hepatitis B after entry into the study; of the 19, seven (36.8%) 
had reactivation of hepatitis B infection. Three were treated prior to reactivation because of 
elevated AFP (n = 1) or HCC (n = 2), and four were treated after reactivation; of these four, 
three had consistent elevations in HBV DNA after treatment (two of them had cancer: 
gastric cancer, colon cancer); the remaining 12 patients who did not reactivate were treated 
because of a family history of HCC (n = 3), undergoing chemotherapy for another cancer (n 
= 2), HCC (n = 2), undergoing immunosuppressive treatment for Crohn’s disease (n = 2), 
chronic AFP elevation (n = 1), receiving immunosuppressive therapy for auto-immune 
hepatitis (n = 1), and presence of cirrhosis (n = 1).
Of the 378 persons who did not have reactivation of HBV infection, 136 (36.0%) 
experienced one or more ALT elevations with 30 (7.9%) persons having ALT ≥ 100 IU/L 
with no increase in HBV DNA ≥ 2000 IU/mL. In addition, 13 persons had an elevation of 
HBV DNA ≥ 2000 IU/mL (median: 3366 IU/mL, range: 2120–42,300 IU/mL) without ever 
having an ALT ≥ 40 IU/L. During 2001–2010, 26 (8.7%) inactive carriers of chronic 
hepatitis B seroconverted to a negative HBsAg for an annual rate of 8.7 sero-conversions per 
1000 carriers and none had reactivation of hepatitis B during follow-up.
Of the 13 cohort members who had a liver biopsy during the study, two inactive carriers had 
minimal fibrosis (Ishak score = 1), and two other had mild fibrosis (Ishak score = 2), but 
none were diagnosed with cirrhosis. Four cohort members developed HCC within 2.7, 4.6, 
6.2, and 7.6 years after study entry; however none met the criteria for reactivated hepatitis B 
infection and none had elevations in HBV DNA based on repeated testing. A total of 28 
(6.8%) inactive carriers died during the study period with an annual mortality rate of 0.9%. 
One inactive carrier died from HCC, two from hepatic failure and one from liver failure 
secondary to cancer of the gallbladder.
5. Discussion
This study measured the incidence of and assessed risk factors for hepatitis B reactivation in 
a cohort of 414 persons in the inactive phase of chronic hepatitis B in Alaska who were 
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followed for an average of 7.4 years. The annual incidence of reactivation was 1.2% and a 
total of 9% experienced reactivation by the end of 2010. The prevalence and incidence of 
reactivation seem to vary by the duration of follow-up and the HBV DNA cut-off point 
considered for reactivation. Studies which followed persons in the inactive phase of chronic 
hepatitis B for less than 5 years, rarely reported occurrence of reactivation among inactive 
carriers although the majority had detectable low levels of HBV DNA [17,18]. Longitudinal 
studies with an average of 7–10 years of follow-up reported a cumulative incidence of 
reactivation ranging from 2.0% to 23.8% [7–9,19], and an annual incidence rate of 
reactivation ranging between 0.4% and 1.6% [9,19,20]. Some studies used an HBV DNA ≥ 
2000 IU/mL (104 copies/mL) to indicate reactivation of infection [9,19], while other studies 
defined reactivation of hepatitis B as HBV DNA ≥ 20,000 IU/mL (105 copies/mL) [7,8] 
which would affect estimates of incidence rates.
In our study, males had a higher risk for and more importantly tended to experience 
reactivation of HBV infection sooner after entry into the study then females. Male sex has 
been previously reported as a risk factor for reactivation [7,9,21], which is consistent with 
increased risk of chronic HBV infection, liver cancer, and death among males compared to 
females with HBV infection [22].
The most important finding in this study was the high risk of reactivation in those with a 
baseline HBV DNA ≥ 1000 IU/mL, which occurred in one quarter of inactive carriers fitting 
this category. Inactive carriers with HBV DNA ≥ 1000 IU/mL had almost a fourfold higher 
incidence rate of reactivation than those with HBV DNA < 1000 IU/mL. The AASLD 
chronic hepatitis B practice guidelines recommend following chronically infected patients 
every 3–12 months depending on disease activity [11]. Our finding suggests the need to 
follow-up inactive carriers with HBV DNA ≥ 1000 IU/mL more frequently than others.
While we found a higher risk for reactivation among inactive carriers with genotype B 
infection, only few inactive carriers in our cohort had genotype B (n = 9) leading to a wide 
confidence interval. A higher likelihood of reactivation was reported among inactive carriers 
with genotype C infection compared to those with genotype B in Taiwan [21,23], while 
longitudinal studies in Europe included mainly homogeneous populations infected with 
genotype D. We had 23 inactive carriers with genotype C, therefore we can rule out that 
having a larger number of genotype C inactive carriers might have influenced the findings.
Although 9% of inactive carriers in our cohort experienced reactivation, very few developed 
advanced liver disease which is consistent with findings from several studies [7,8,10,19,20]. 
It is notable that none of the four inactive carriers who were diagnosed with HCC during the 
study had reactivation. However, these inactive carriers were treated as soon as HCC was 
diagnosed which might have been responsible for lowering their risk. Our findings reinforce 
the importance of regular surveillance for HCC among HBV infected persons who remain in 
the inactive phase.
This study has several limitations. Data on other risk factors that might potentially influence 
reactivation such as alcohol intake, smoking, diabetes status, and HBV precore and basal 
core mutations were unavailable. Moreover, biopsy results were lacking from a large 
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proportion of the study population because most of these individuals live in remote villages 
making it impossible to examine them on a regular basis. We could not calculate the 
incidence of reactivation by the age at HBV infection, as the exact time of infection was not 
available for the majority of inactive carriers; however a large prospective study conducted 
in this population showed that most persons who became chronically infected with HBV 
infection were exposed to HBV at a very young age [24].
Despite these limitations, the findings in this study are of significant benefit and might help 
identify persons in the inactive phase of chronic hepatitis B who need closer follow-up. 
Although the incidence of reactivation is low after almost 10 years of follow-up, males, and 
persons having HBV DNA ≥ 1000 IU/mL might need more frequent follow-up, compared to 
others in the inactive phase. In addition those who experience reactivation might need to be 
treated sooner after reactivation in order to avoid complications of HBV infection such as 
cirrhosis and liver cancer.
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Proportion of hepatitis B reactivation by sex during the study time.
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Table 1
Demographic and clinical characteristics of the cohort of persons in the inactive phase of chronic hepatitis B – 
Alaska, 2001–2010.
n (N = 414) %
Demographic characteristics
 Age at study entry (years)
  18–29 117 28.3
  30–39 113 27.3
  40–49 92 22.2
  50+ 92 22.2
Sex (males) 179 43.2
Ethnic group
 Alaska/American Indian 31 7.5
 Aleut 30 7.2
 Eskimo 353 85.3
Clinical characteristics
 Body mass indexa
  Normal (<25) 114 27.5
  Overweight (25–29) 106 25.6
  Obese (≥30) 148 35.7
ALT at study entry (mean ± SD) (IU/L) 22.3 ± 7.4
HBV DNA levels (IU/mL) at study entry
 <29 185 44.7
 29–199 55 13.3
 200–999 119 28.7
 1000–1999 55 13.3
HBV genotypeb
 A 57 13.8
 B 9 2.2
 C 23 5.6
 D 209 50.5
 F 71 17.1
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Table 2
Reactivation of hepatitis B by age at study entry — Alaska, 2001–2010.
Age at study entry (years) n/total Percent reactivation (%) Person-years of follow-up Annual Incidence of reactivation (per 
100 person-years)
18–29 13/117 11 832 1.6
30–39 8/113 7 815 1.0
40–49 3/92 3 678 0.4
50+ 12/92 13 659 1.8
Total 36/414 9 2984 1.2
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Table 3
Hepatitis B reactivation by demographic and clinical characteristics.
Proportion of reactivation Survival analysis
n/total % Unadjusted HR (95%CI)
Demographic characteristics
 Age at study entry (years)
  18–29 13/117 11% 1.00
  30–39 8/113 7% 0.62 (0.36–1.50)
  40–49 3/92 3% 0.28 (0.08–0.99)*
  50+ 12/92 13% 1.14 (0.52–2.49)
Sex
 Females 14/235 6% 1.00
 Males 22/179 12% 2.33 (1.19–4.57)*
Ethnic group
 Alaska/American Indian 2/31 6% 0.72 (0.17–3.00)
 Aleut 5/30 17% 2.25 (0.87–5.82)
 Eskimo 29/353 8% 1.00
Clinical characteristics
 Age at first positive HBsAg (years)
  <10 15/137 11% 1.00
  10–19 6/95 6% 0.56 (0.22–1.45)
  20–29 3/78 4% 0.32 (0.09–1.12)
  30–39 8/60 13% 1.12 (0.47–2.64)
  40–49 1/23 4% 0.39 (0.05–2.94)
  50+ 3/21 14% 1.35 (0.39–4.68)
Body mass index
 Normal (<25) 12/114 11% 1.00
 Overweight (25–29) 14/106 13% 1.30 (0.60–2.81)
 Obese (≥30) 10/148 7% 0.61 (0.26–1.41)
HBV DNA levels) at study entry (IU/mL)
 <29 8/185 4% 1.00
 29–199 5/55 9% 2.21 (0.72–6.75)
 200–999 10/119 8% 2.05 (0.81–5.20)
 1000–1999 13/55 24% 5.84 (2.42–14.1)***
HBV genotype
 A 5/57 9% 1.18 (0.36–3.86)
 B 2/9 22% 6.76 (1.36–33.8)*
 C 2/23 9% 1.14 (0.23–5.65)
 D 18/209 9% 1.10 (0.44–2.79)
 F 6/71 8% 1.00
HR, Hazard Ratio; CI, confidence interval; HBV, hepatitis B virus.
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Table 4
Factors associated with hepatitis B reactivation, multivariate cox proportional hazard model — Alaska, 2001–
2010.
Variable Adjusted Hazard Ratio (95%CI) P-Value
Age at study entry (years)
 18–29 1.00
 30–39 0.34 (0.12, 0.90) 0.03
 40–49 0.20 (0.05, 0.70) 0.01
 50+ 0.77 (0.33, 1.77) 0.53
Sex
 Females 1.00
 Males 2.41 (1.17, 4.96) 0.01
HBV DNA levels at study entry (IU/mL)
 <29 1.00
 29–199 2.51 (0.75, 8.36) 0.13
 200–999 2.28 (0.80, 6.46) 0.12
 1000–1999 7.61 (2.81, 20.6) <0.001
HBV genotype
 Non-B 1.00
 B 6.08 (1.32, 28.0) 0.02
HR, Hazard Ratio; CI, confidence interval; HBV, hepatitis B virus
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